Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea

International Journal of Antimicrobial Agents

Volumn 28, Issue 4, 2006, Pages 333-339

  Lee, Dong Gun ^a   Choi, Su Mi ^a   Shin, Wan Shik ^a   Lah, Hyon Oh ^a   Yim, Dong Seok ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Meropenem; MIC; Neutropenia; Population pharmacokinetics; Simulation

Indexed keywords

CEFADROXIL; CREATININE; MEROPENEM;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-BACTERIAL AGENTS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEVER; HUMANS; KOREA; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NEUTROPENIA; POPULATION; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 33748742964     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.05.033     Document Type: Article

References (19)

1. Jorgensen J.H., Maher L.A., and Howell A.W. Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase- and non-enzyme-mediated resistance to ampicillin. Antimicrob Agents Chemother 35 (1991) 600-602
2. Moellering Jr. R.C., Eliopoulos G.M., and Sentochnik D.E. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother 24 Suppl. A (1989) 1-7
3. Nord C.E., Lindmark A., and Persson I. Susceptibility of anaerobic bacteria to meropenem. J Antimicrob Chemother 24 Suppl. A (1989) 113-117
4. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
5. Ip M., Au C., Cheung S.W., Chan C.Y., and Cheng A.F. A rapid high-performance liquid chromatographic assay for cefepime, cefpirome and meropenem. J Antimicrob Chemother 42 (1998) 121-123
6. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; 14th Informational Supplement. Document M100-S14. Wayne, PA: NCCLS; 2004.
7. Dreetz M., Hamacher J., Eller J., et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 40 (1996) 105-109
8. Fish D.N., and Singletary T.J. Meropenem, a new carbapenem antibiotic. Pharmacotherapy 17 (1997) 644-669
9. Mouton J.W., and van den Anker J.N. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 28 (1995) 275-286
10. Moon Y.S., Chung K.C., and Gill M.A. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 24 Suppl. 2 (1997) S249-S255
11. Ariano R.E., Nyhlen A., Donnelly J.P., Sitar D.S., Harding G.K., and Zelenitsky S.A. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 39 (2005) 32-38
12. Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish Study Group. Eur J Clin Microbiol Infect Dis 1997;16:797-802.
13. Choi S., Lee D., Park Y., et al. Infections in patients with acute leukemia: comparison of induction chemotherapy group and reinduction chemotherapy group. J Infect Chemother 35 (2003) 78-85
14. Yoo J.H., Lee D.G., Choi S.M., et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 34 (2004) 497-504
15. Park S.H., Choi S.M., Lee D.G., et al. Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. J Korean Med Sci 21 (2006) 199-207
16. Lee D.G., Choi S.M., Choi J.H., et al. Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean J Intern Med 17 (2002) 38-44
17. Lee H., Yong D., Lee K., et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2004. Korean J Clin Microbiol 8 (2005) 66-73
18. Rhomberg P.R., and Jones R.N. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 47 (2003) 365-372
19. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother 48 (2004) 2464-2470